ReportAlert.info - Amgen (NASDAQ:AMGN) Publishes 2012 Environmental Sustainability Report

The report illustrates how environmental efforts at the company improve business efficiency, benefit communities, and support the company's mission to develop innovative medicines.
May 28, 2013 6:00 AM ET

May 28, 2013 /3BL Media/ - Amgen has released its 2012 environmental sustainability report that provides results from conservation initiatives, a summary of 2012 plan achievements, and an introduction to the new 2020 plan. The report illustrates how environmental efforts at Amgen improve business efficiency, benefit communities, and support the company’s mission to develop innovative medicines.

To read Amgen’s report, please visit environment.amgen.com.

Report highlights:

  • Amgen has achieved all of its 2012 environmental targets and has embarked on a 2020 plan with new targets for sustainability.
  • From 2008 through 2012, Amgen realized more than $24 million in cost savings by implementing strategic sustainability initiatives.
  • Through programs such as Green Biology and Green Chemistry, Amgen is integrating environmental sustainability practices across the many complex activities it undertakes to serve patients.
  • Amgen’s 2012 report has been confirmed at a “C+” application level by the Global Reporting Initiative.
  • Environmental sustainability data in the report were successfully verified by Bureau Veritas. This verification is an important step in Amgen’s overall Environmental Sustainability plan to give stakeholders confidence that the data are accurate.

Feedback on the report is welcome at esfeedback@amgen.com

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen